

IDAHO FALLS, Idaho and FÜRSTENFELDBRUCK, Germany, January 7, 2025

International Isotopes, a leading provider of medical isotopes and nuclear medicine solutions, is proud to announce its exclusive partnership with SCINTOMICS Molecular, Applied Theranostics Technologies GmbH (ATT), a global leader in radiopharmaceutical synthesis technology. Under this agreement, International Isotopes will distribute, install, and service ATT's state-of-the-art synthesis modules throughout the United States and Canada, along with providing consumables and ongoing support.

INIS specializes in the development, production, and distribution of radiopharmaceuticals and medical devices for nuclear medicine applications. The company supports diagnostic and therapeutic procedures by providing high-purity isotopes and innovative devices used in radiopharmaceutical production and patient care.



ATT's innovative equipment is designed to streamline the production of radiopharmaceuticals, enabling radiopharmacies and cyclotron facilities to produce radioisotopes for critical diagnostic and therapeutic applications with greater efficiency and precision. This partnership marks an important step in expanding access to advanced technology in the U.S. and Canadian nuclear medicine markets.

"We are thrilled to collaborate with ATT and with the opportunity to expand and accelerate the use of their world-class synthesis modules in North America. This partnership aligns with our mission to support theranostics providers with cutting-edge solutions that enhance the production of life-changing radiopharmaceuticals," said Shahe Bagerdjian President and CEO of International Isotopes. "We are delighted to welcome INIS as a strong and experienced partner who shares our deep commitment to advancing radiopharmacy," says Andrea Maugg, Managing Director of Scintomics Molecular, Applied Theranostics Technologies GmbH. (ATT) "This partnership marks an exciting milestone, and we are confident that both existing and future users of our synthesis modules and products in North America will greatly benefit from the enhanced professional support and valuable insights for new projects that INIS brings to the table."

As part of the agreement, International Isotopes will provide a comprehensive suite of services, including equipment sales, installation, maintenance, and technical support. In addition, the company will manage the sales and supply of consumables, including precursors and production sets, to ensure uninterrupted operation of SCI-att GRP Modules.

SCI-att's equipment is already trusted by leading institutions worldwide for its reliability, ease of use, and compliance with regulatory standards. This collaboration will increase the number U.S. radiopharmacies that have access to the tools and support needed to meet the growing demand for nuclear medicine procedures.

About International Isotopes Inc.

International Isotopes Inc. (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. INIS manufactures and supplies generic sodium iodide I-131 radiopharmaceutical drug product for hyperthyroidism and thyroid cancer. INIS manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards. The Company also manufactures Cobalt-60 sealed source products and provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. INIS recently launched a manufacturing joint venture with Alpha Nuclides, to bring INIS and RadQual products into China via Radnostix China.

About SCINTOMICS Molecular, Applied Theranostics Technologies GmbH (ATT)

ATT specializes in advanced synthesis technology tailored for the production of radiopharmaceuticals. Their cutting-edge synthesis modules streamline the preparation of radioactive isotopes by automating complex chemical processes. These units are primarily used in radiopharmacies and cyclotron facilities to produce radioisotopes for diagnostic imaging and therapeutic procedures. ATT's systems are engineered for precision, reliability, and compliance with stringent medical and industrial standards, ensuring consistent and high-quality radioisotope production.

International Isotopes Inc. Safe Harbor Statement

Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including its Annual Report on Form 10-K for the year ended December 31, 2023. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For more information about ATT, contact:

Andrea Maugg
Managing Director
a.maugg@sci-att.com
sci-att.com